Optimizing Biomarker Testing in Your Practice: Leveraging In-House Testing Strategies - Episode 10

Decentralization of Biomarker Testing: Expanding Access to Targeted Therapies and Clinical Trials in Underserved Populations

,

Panelists discuss how decentralizing biomarker testing improves access to targeted therapies and clinical trials for underserved populations by reducing geographic and systemic barriers, fostering equity in cutting-edge health care.

EP. 1: Key Considerations When Ordering Biomarker Testing
EP. 2: The Importance of Broad Biomarker Testing: Uncovering Actionable Targets Across Tumor Types
EP. 3: When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis
EP. 4: Centralized vs Decentralized Biomarker Testing: Workflow, Control, and Collaboration Insights
EP. 5: In-House Comprehensive Genomic Profiling: Expert Insight Into Balancing Benefits and Challenges
EP. 6: Implementing In-House Biomarker Testing: Rationale and Key Considerations
EP. 7: Optimizing In-House Testing: Enhancing Efficiency for Timely Results and Treatment Decisions
EP. 8: Enhancing Multidisciplinary Coordination and Treatment Planning Through In-House Testing
EP. 9: Impact of In-House Testing on Improved Cancer Care: Timely Decisions and Enhanced Treatment Accuracy
Now Viewing
EP. 10: Decentralization of Biomarker Testing: Expanding Access to Targeted Therapies and Clinical Trials in Underserved Populations
EP. 11: Mitigating Socioeconomic Disparities Through Decentralized Testing: Overcoming Barriers to Access and Equity

Video series above is prompted by the following:

  • What are your thoughts on how decentralization of biomarker testing might address access to targeted therapies and clinical trials in underserved populations?
  • Explore how testing decentralization can bridge gaps in access to cutting-edge treatments and clinical trials for marginalized or geographically distant populations.